Base de datos : MEDLINE
Búsqueda : adenocarcinoma [Palabras]
Referencias encontradas : 233062 [refinar]
Mostrando: 1 .. 10   en el formato [Detallado]

página 1 de 23307 va a la página                         

  1 / 233062 MEDLINE  
              next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:29524849
[Au] Autor:Di Martino A; Trusova ME; Postnikov PS; Sedlarik V
[Ad] Dirección:Centre of Polymer Systems, University Institute, Tomas Bata University in Zlin, Tr.Tomas Bati, 5678, 76001, Zlin, Czech Republic; Research School in Chemistry & Applied Biomedical Sciences, Tomsk Polytechnic University, Lenin Av. 30, 634050 Tomsk, Russian Federation. Electronic address: dimartin
[Ti] Título:Branched poly (lactic acid) microparticles for enhancing the 5-aminolevulinic acid phototoxicity.
[So] Fuente:J Photochem Photobiol B;181:80-88, 2018 Mar 03.
[Is] ISSN:1873-2682
[Cp] País de publicación:Switzerland
[La] Idioma:eng
[Ab] Resumen:An innovative microcarrier based on a carboxy-enriched and branched polylactic acid derivative was developed to enhance the in vitro phototoxicity of the photosensitizer and prodrug 5-aminolevulinic. Microparticles, prepared by double emulsion technique and loaded with the prodrug were carefully characterized and the effect of the polymer structure on the chemical, physical and biological properties of the final product was evaluated. Results showed that microparticles have a spherical shape and ability to allocate up to 30 µg of the photosensitizer per mg of carrier despite their difference in solubility. Release studies performed in various simulated physiological conditions demonstrate the influence of the branched structure and the presence of the additional carboxylic groups on the release rate and the possibility to modulate it. In vitro assays conducted on human epithelial adenocarcinoma cells proved the not cytotoxicity of the carriers in a wide range of concentrations. The hemocompatibility and surface proteins adsorption were evaluated at different microparticles concentrations to evaluate the safety and estimate the possible microparticles residential time in the bloodstream. The advantages, of loading 5-aminolevulinic acid in the prepared carrier has been deeply described in terms of enhanced phototoxicity, compared to the free 5-aminolevulinic acid formulation after irradiation with light at 635 nm. The obtained results demonstrate the advantages of the prepared derivative compared to the linear polylactide for future application in photodynamic therapy based on the photosensitizer 5-aminolevulinic acid.
[Pt] Tipo de publicación:JOURNAL ARTICLE
[Em] Mes de ingreso:1803
[Cu] Fecha actualización por clase:180310
[Lr] Fecha última revisión:180310
[St] Status:Publisher


  2 / 233062 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:29524521
[Au] Autor:Akizuki R; Maruhashi R; Eguchi H; Kitabatake K; Tsukimoto M; Furuta T; Matsunaga T; Endo S; Ikari A
[Ad] Dirección:Laboratory of Biochemistry, Department of Biopharmaceutical Sciences, Gifu Pharmaceutical University, Japan.
[Ti] Título:Decrease in paracellular permeability and chemosensitivity to doxorubicin by claudin-1 in spheroid culture models of human lung adenocarcinoma A549 cells.
[So] Fuente:Biochim Biophys Acta;, 2018 Mar 07.
[Is] ISSN:0006-3002
[Cp] País de publicación:Netherlands
[La] Idioma:eng
[Ab] Resumen:Chemotherapy resistance is a major problem in the treatment of cancer, but the underlying mechanisms are not fully understood. We found that the expression levels of claudin-1 (CLDN1) and 3, tight junctional proteins, are upregulated in cisplatin (CDDP)-resistant human lung adenocarcinoma A549 (A549R) cells. A549R cells showed cross-resistance to doxorubicin (DXR). Here, the expression mechanism and function of CLDN1 and 3 were examined. CLDN1 and 3 were mainly localized at tight junctions concomitant with zonula occludens (ZO)-1, a scaffolding protein, in A549 and A549R cells. The phosphorylation levels of Src, MEK, ERK, c-Fos, and Akt in A549R cells were higher than those in A549 cells. The expression levels of CLDN1 and 3 were decreased by LY-294002, a phosphoinositide 3-kinase (PI3K) inhibitor, and BAY 11-7082, an NF-κB inhibitor. The overexpression of CLDN1 and 3 decreased the paracellular permeability of DXR in A549 cells. Hypoxia levels in A549R and CLDN1-overexpressing cells (CLDN1/A549) were greater than those in A549, mock/A549, and CLDN3/A549 cells in a spheroid culture model. In contrast, accumulation in the region inside the spheroids and the toxicity of DXR in A549R and CLDN1/A549 cells were lower than those in other cells. Furthermore, the accumulation and toxicity of DXR were rescued by CLDN1 siRNA in A549R cells. We suggest that CLDN1 is upregulated by CDDP resistance through activation of a PI3K/Akt/NF-κB pathway, resulting in the inhibition of penetration of anticancer drugs into the inner area of spheroids.
[Pt] Tipo de publicación:JOURNAL ARTICLE
[Em] Mes de ingreso:1803
[Cu] Fecha actualización por clase:180310
[Lr] Fecha última revisión:180310
[St] Status:Publisher


  3 / 233062 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:29515739
[Au] Autor:Agyemang-Yeboah F; Yorke J; Obirikorang C; Batu EN; Acheampong E; Frempong EA; Anto EO; Amankwaa B
[Ad] Dirección:Department of Molecular Medicine, School of Medical Science, Kwame Nkrumah University of Science and Technology (KNUST), Kumasi, Ghana.
[Ti] Título:Patterns and presentations of colorectal cancer at Komfo-Anokye teaching hospital Kumasi, Ghana.
[So] Fuente:Pan Afr Med J;28:121, 2017.
[Is] ISSN:1937-8688
[Cp] País de publicación:Uganda
[La] Idioma:eng
[Ab] Resumen:Introduction: Colorectal cancer is a major cause of morbidity and mortality globally and its incidence is increasing in developing countries. This study determined the incidence, clinical features and the histopathological patterns of colorectal cancer at Komfo Anokye Teaching Hospital (KATH), Kumasi, Ghana. Methods: A retrospective review of all colorectal cancer cases over a six year period from (2009-2015) presented to the Surgical and Oncological Department of KATH. Patients' records were retrieved and information on their demographics, clinical and pathological presentations recorded. Results: In all, 221 cases of colorectal cancer were identified over the study period. The mean age was 54 ± 16.8 and ranged from 16 to 90 years. Sixteen (7.24%) had family history of cancer and the prevalence of comorbidities was (24.89%). The commonest clinical symptoms presented were weight loss (44.80%), bleeding per rectum (39.82%) and abdominal pain (38.91%) Majority of the patients presented with rectal cancers (48.87%). Microscopically, adenocarcinoma (68.33%) was the most common histopathological type. According to Tumour Node Metastasis (TNM) staging of cancer, majority of the patients 89(40.27%) were identified as being in late stage (TNM Stage III). The overall crude annual incidence was 4.62 per 100000 populations. The age specific standardized incidence rate was 7.93 per 100,000 population. Conclusion: This study has clearly showed a high incidence in colorectal cancer at KATH, with similar trends in clinico-pathological patterns comparable to that of most African countries. These include predominance of rectal cancers, high incidence among younger people and delayed presentation of the disease at advanced stage.
[Pt] Tipo de publicación:JOURNAL ARTICLE
[Em] Mes de ingreso:1803
[Cu] Fecha actualización por clase:180311
[Lr] Fecha última revisión:180311
[St] Status:In-Process
[do] DOI:10.11604/pamj.2017.28.121.12927


  4 / 233062 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:29515724
[Au] Autor:Motsumi MJ; Motlaleselelo P; Ayane G; Sesay SO; Valdes JR
[Ad] Dirección:University of Botswana, Department of Surgery, Sir Ketumile Masire University Hospital, PO Box, Mogoditshane, Botswana.
[Ti] Título:A case report of a giant appendiceal mucocele and literature review.
[So] Fuente:Pan Afr Med J;28:106, 2017.
[Is] ISSN:1937-8688
[Cp] País de publicación:Uganda
[La] Idioma:eng
[Ab] Resumen:A 43-year-old female presented at the accident and emergency department of Princess Marina Hospital, Gaborone, Botswana. She reported a deep dull aching pain of two years duration in the right iliac fossa that has been progressively becoming worse. Ultrasound revealed a large sausage like cystic mass extending from the pelvis up to the medial aspect of the ascending colon. CT scan showed a large sausage like cystic mass extending from the pelvis up to the hepatic flexure of the colon with the cecum displaced. No metastatic features were seen. We made an impression of appendiceal mucocele. A semi-elective laparotomy was scheduled. Intraoperative findings: a giant intact cystic distended appendix with involved base, displacing the cecum cranially. A right hemicolectomy was performed. The histopathological results revealed a low-grade appendicular mucinous neoplasm with no lymph node involvement. The surgical margins were free. The patient recovered uneventfully.
[Pt] Tipo de publicación:JOURNAL ARTICLE
[Em] Mes de ingreso:1803
[Cu] Fecha actualización por clase:180311
[Lr] Fecha última revisión:180311
[St] Status:In-Process
[do] DOI:10.11604/pamj.2017.28.106.13832


  5 / 233062 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:29509593
[Au] Autor:Iarrobino NA; Gill B; Bernard ME; Mishra MV; Champ CE
[Ad] Dirección:University of Pittsburgh School of Medicine.
[Ti] Título:Targeting Tumor Metabolism With Statins During Treatment for Advanced-stage Pancreatic Cancer.
[So] Fuente:Am J Clin Oncol;, 2018 Mar 05.
[Is] ISSN:1537-453X
[Cp] País de publicación:United States
[La] Idioma:eng
[Ab] Resumen:INTRODUCTION: A growing body of preclinical data suggests that statins may exert potent antitumor effects, yet the interactions of these medications with standard therapies and clinical outcomes in this population is less clear. We assessed the impact of statin use on outcomes in patients with advanced-stage pancreatic adenocarcinoma undergoing various treatments. MATERIALS AND METHODS: After institutional review board approval, we conducted a retrospective-cohort study consisting of 303 newly diagnosed advanced-stage pancreatic adenocarcinoma patients to determine the impact of statin use on outcomes. Univariate and multivariable Cox proportional hazard regression models were utilized to estimate hazard ratios (HRs). Time-to-event was estimated using Kaplan-Meier survival analysis for overall survival, distant metastasis, and locoregional failure. Baseline and active statin usage were assessed and to mitigate risk of immortal time bias, subanalysis excluding patients with under 6 months of follow-up was conducted. RESULTS: Both prior (P=0.021) and active (P=0.030) statin usage correlated with improved survival in this cohort. Surgery, chemoradiation, and statin use improved 2-year survival rates (84.1% vs. 55.0%; P<0.001). On multivariable analysis, statin exposure was associated with overall survival (HR, 0.662; P=0.027) and trended to significance for freedom from distant metastasis (HR, 0.577; P=0.060). Comorbid conditions were not significantly associated with outcomes. CONCLUSIONS: Statin use was associated with improved overall survival in advanced-stage pancreatic adenocarcinoma patients. This data supports previous findings in early-stage pancreatic adenocarcinoma and other cancer sites. To our knowledge this is the first report to examine the efficacy of statin use as a supplementary treatment option in advanced-stage pancreatic adenocarcinoma patients.
[Pt] Tipo de publicación:JOURNAL ARTICLE
[Em] Mes de ingreso:1803
[Cu] Fecha actualización por clase:180311
[Lr] Fecha última revisión:180311
[St] Status:Publisher
[do] DOI:10.1097/COC.0000000000000433


  6 / 233062 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:29506569
[Au] Autor:Sahin H; Meydanli MM; Sari ME; Yalcin I; Çoban G; Ozkan NT; Cuylan ZF; Erdem B; Gungorduk K; Akbayir Ö; Dede M; Salman MC; Güngör T; Ayhan A
[Ad] Dirección:Department of Gynecologic Oncology, Zekai Tahir Burak Women's Health Training and Research Hospital, Faculty of Medicine, University of Health Sciences, Ankara, Turkey. hanifi.81_@hotmail.com.
[Ti] Título:Does the primary route of spread have a prognostic significance in stage III non-serous epithelial ovarian cancer?
[So] Fuente:J Ovarian Res;11(1):21, 2018 Mar 05.
[Is] ISSN:1757-2215
[Cp] País de publicación:England
[La] Idioma:eng
[Ab] Resumen:BACKGROUND: The purpose of this retrospective study was to determine the prognosis of non-serous epithelial ovarian cancer (EOC) patients with exclusively retroperitoneal lymph node (LN) metastases, and to compare the prognosis of these women to that of patients who had abdominal peritoneal involvement. METHODS: A multicenter, retrospective department database review was performed to identify patients with stage III non-serous EOC at 7 gynecologic oncology centers in Turkey. Demographic, clinicopathological and survival data were collected. The patients were divided into three groups based on the initial sites of disease: 1) the retroperitoneal (RP) group included patients who had positive pelvic and /or para-aortic LNs only. 2) The intraperitoneal (IP) group included patients with > 2 cm IP dissemination outside of the pelvis. These patients all had a negative LN status, 3) The IP / RP group included patients with > 2 cm IP dissemination outside of the pelvis as well as positive LN status. Survival data were compared with regard to the groups. RESULTS: We identified 179 women with stage III non-serous EOC who were treated at 7 participating centers during the study period. The median age of the patients was 53 years, and the median duration of follow-up was 39 months. There were 35 (19.6%) patients in the RP group, 72 (40.2%) in the IP group and 72 (40.2%) in the IP/RP group. The 5-year disease-free survival (DFS) rates for the RP, the IP, and IP/RP groups were 66.4%, 37.6%, and 25.5%, respectively (p = 0.002). The 5-year overall survival (OS) rate for the RP group was significantly longer when compared to those of the IP, and the IP/RP groups (74.4% vs. 54%, and 36%, respectively; p = 0.011). However, we were not able to define "RP only disease" as an independent prognostic factor for increased DFS or OS. CONCLUSIONS: Primary non-serous EOC patients with node-positive-only disease seem to have better survival when compared to those with extra-pelvic peritoneal involvement.
[Pt] Tipo de publicación:JOURNAL ARTICLE
[Em] Mes de ingreso:1803
[Cu] Fecha actualización por clase:180311
[Lr] Fecha última revisión:180311
[St] Status:In-Process
[do] DOI:10.1186/s13048-018-0393-0


  7 / 233062 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:29474858
[Au] Autor:Cheong DHJ; Arfuso F; Sethi G; Wang L; Hui KM; Kumar AP; Tran T
[Ad] Dirección:Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, 117593, Singapore.
[Ti] Título:Molecular targets and anti-cancer potential of escin.
[So] Fuente:Cancer Lett;422:1-8, 2018 Feb 21.
[Is] ISSN:1872-7980
[Cp] País de publicación:Ireland
[La] Idioma:eng
[Ab] Resumen:Escin is a mixture of triterpenoid saponins extracted from the horse chestnut tree, Aesculus hippocastanum. Its potent anti-inflammatory and anti-odematous properties makes it a choice of therapy against chronic venous insufficiency and odema. More recently, escin is being actively investigated for its potential activity against diverse cancers. It exhibits anti-cancer effects in many cancer cell models including lung adenocarcinoma, hepatocellular carcinoma and leukemia. Escin also attenuates tumor growth and metastases in various in vivo models. Importantly, escin augments the effects of existing chemotherapeutic drugs, thereby supporting the role of escin as an adjunct or alternative anti-cancer therapy. The beneficial effects of escin can be attributed to its inhibition of proliferation and induction of cell cycle arrest. By regulating transcription factors/growth factors mediated oncogenic pathways, escin also potentially mitigates chronic inflammatory processes that are linked to cancer survival and resistance. This review provides a comprehensive overview of the current knowledge of escin and its potential as an anti-cancer therapy through its anti-proliferative, pro-apoptotic, and anti-inflammatory effects.
[Pt] Tipo de publicación:JOURNAL ARTICLE
[Em] Mes de ingreso:1802
[Cu] Fecha actualización por clase:180310
[Lr] Fecha última revisión:180310
[St] Status:Publisher


  8 / 233062 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:29455047
[Au] Autor:Bunting D; Berrisford R; Wheatley T; Humphreys L; Ariyarathenam A; Sanders G
[Ad] Dirección:Peninsula Oesophago-gastric Surgery Unit, Derriford Hospital, Plymouth, Devon, PL3 5AN, UK. Electronic address: davidbunting@nhs.net.
[Ti] Título:Prospective cohort study of neoadjuvant therapy toxicity in the treatment of oesophageal adenocarcinoma.
[So] Fuente:Int J Surg;52:126-130, 2018 Feb 15.
[Is] ISSN:1743-9159
[Cp] País de publicación:England
[La] Idioma:eng
[Ab] Resumen:BACKGROUND: Early studies investigating the benefits of neoadjuvant therapy in oesophageal cancer showed conflicting results, taking many years before a survival advantage was demonstrated in randomised trials. Gains are modest, limited by progressive disease and toxicity. This study aimed to investigate the relationship between neoadjuvant therapy-associated toxicity and clinical outcomes including survival in patients with potentially curable oesophageal adenocarcinoma. MATERIALS AND METHODS: A cohort of 286 patients undergoing neoadjuvant therapy followed by surgical resection at a single institution was identified from a prospective database. Adverse events from neoadjuvant therapy were recorded and graded. Patients were divided into two groups according to whether they suffered toxicity or not. Clinical outcomes including whether patients completed the neoadjuvant course, whether they proceeded to resection and overall survival, were compared between the groups. RESULTS: Neoadjuvant therapy-related toxicity was identified in 67/286 patients. 46 patients suffered severe, life-threatening or fatal adverse events. In patients with toxicity, 47% did not complete the chemotherapy course compared to 17% without toxicity, RR 2.7 (95%CI 1.7-4.4), (P < 0.001). In patients suffering toxicity, 17.9% failed to proceed to resection compared with 7.8% in those without toxicity, RR 2.3 (95%CI 1.2-4.6) P = 0.02. Median overall survival was shorter in patients suffering toxicity (20.7 months) compared to those without toxicity (37.8 months), P = 0.008. When patients failing to proceed to resection were excluded, median overall survival was shorter in patients suffering toxicity (26.2 months) compared with those without toxicity (47.8), P = 0.039. CONCLUSION: Neoadjuvant therapy-related toxicity is common and can have serious consequences including failure to complete chemotherapy cycles, a higher risk of not proceeding to surgical resection and poorer overall survival. Efforts should be made to reduce toxicity and research should aim to identify responders and factors predictive of toxicity.
[Pt] Tipo de publicación:JOURNAL ARTICLE
[Em] Mes de ingreso:1802
[Cu] Fecha actualización por clase:180310
[Lr] Fecha última revisión:180310
[St] Status:Publisher


  9 / 233062 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:29454093
[Au] Autor:Huang WJ; Wang Y; Liu S; Yang J; Guo SX; Wang L; Wang H; Fan YF
[Ad] Dirección:Hepatobiliary Surgery, Zhujiang Hospital, Southern Medical University/The Second School of Clinical Medicine, Southern Medical University, Industrial Road No.253, Guangzhou, Guangdong 510280, China; Institute of Hepatopancreatobiliary, Surgery Southwest Hospital, Third Military Medical University (A
[Ti] Título:Silencing circular RNA hsa_circ_0000977 suppresses pancreatic ductal adenocarcinoma progression by stimulating miR-874-3p and inhibiting PLK1 expression.
[So] Fuente:Cancer Lett;422:70-80, 2018 Feb 15.
[Is] ISSN:1872-7980
[Cp] País de publicación:Ireland
[La] Idioma:eng
[Ab] Resumen:Circular RNAs (CircRNAs) are a novel type of endogenous noncoding RNAs that regulate target gene expression by interacting with microRNA (miRNA). Emerging evidence shows that dysregulation of circRNAs plays important roles in biological and pathological processes, including cancer development and progression. The functional role of circRNA in PDAC (pancreatic ductal adenocarcinoma) remains to be investigated. In this study, high throughput microarray assay revealed that hsa_circ_0000977 was aberrantly up-regulated in pancreatic cancer tissues; this was also validated by qRT-PCR. Silencing hsa_circ_0000977 suppressed pancreatic cancer cell proliferation and induced cell cycle arrest, which was simulated by hsa-miR-874-3p mimics and blocked by hsa-miR-874-3p inhibitor. Bioinformatics analysis predicted that there is an hsa_circ_0000977/hsa-miR-874-3p/PLK1 (Polo like kinase 1) axis in pancreatic cancer progression. Dual-luciferase reporter system and FISH assay validated the direct interaction of hsa_circ_0000977, hsa-miR-874-3p, and PLK1. Western blot verified that inhibition of hsa_circ_0000977 decreased PLK1 expression. Furthermore, silencing hsa_circ_0000977 suppressed pancreatic cancer growth in vivo. Altogether, silencing hsa_circ_0000977 suppresses progression of pancreatic cancer by interacting with hsa-miR-874-3p and decreasing inhibiting PLK1 expression. Our results may provide a promising strategy for future diagnosis and treatment of pancreatic cancer.
[Pt] Tipo de publicación:JOURNAL ARTICLE
[Em] Mes de ingreso:1802
[Cu] Fecha actualización por clase:180310
[Lr] Fecha última revisión:180310
[St] Status:Publisher


  10 / 233062 MEDLINE  
              first record previous record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:29443014
[Au] Autor:Weinreb I; Bishop JA; Chiosea SI; Seethala RR; Perez-Ordonez B; Zhang L; Sung YS; Chen CL; Assaad A; Oliai BR; Antonescu CR
[Ad] Dirección:Department of Pathology, University Health Network.
[Ti] Título:Recurrent RET Gene Rearrangements in Intraductal Carcinomas of Salivary Gland.
[So] Fuente:Am J Surg Pathol;42(4):442-452, 2018 Apr.
[Is] ISSN:1532-0979
[Cp] País de publicación:United States
[La] Idioma:eng
[Ab] Resumen:Intraductal carcinoma (IC) is the World Health Organization designation for lesions previously called low-grade cribriform cystadenocarcinoma. The relationship of IC to salivary duct carcinoma (SDC) is controversial, but currently these are considered distinct entities. It is hypothesized that IC and SDC should have different genomic signatures that may be identifiable by next-generation sequencing. A total of 23 ICs were identified: 14 pure IC and 9 invasive carcinomas with an intraductal component. Five invasive carcinomas were subjected to next-generation paired-end RNA sequencing. Data analysis was performed using FusionSeq and Mutation detection algorithms (MuTect and VarScan) for variant callers. Gene fusion candidates were validated by fluorescence in situ hybridization and reverse transcription polymerase chain reaction, and mutations by Sanger sequencing. Among the 9 invasive carcinomas, all except 1 were apocrine SDCs with an intraductal component. The remaining case showed typical intercalated duct type IC with invasive adenocarcinoma. The 14 pure ICs had typical intercalated duct features (2 showed hybrid intercalated/apocrine features). RNA sequencing predicted a NCOA4-RET fusion, confirmed by reverse transcription polymerase chain reaction, in the intercalated duct type IC invasive component. Six additional cases of pure IC showed RET rearrangement by fluorescence in situ hybridization (7/15=47%). No apocrine carcinomas showed RET rearrangement. RNA sequencing and Sanger sequencing identified PIK3CA (p.E545K/p.H1047R) and/or HRAS (p.Q61R) hotspot mutations in 6 of 8 (75%) apocrine carcinomas. In conclusion, 2 distinctive types of intraductal lesions are emerging based on molecular analysis. Classic intercalated type ICs commonly harbor fusions involving RET and rarely show widespread invasion. Apocrine intraductal lesions are typically associated with widespread invasion with no pure examples and show similar PIK3CA and HRAS mutations to SDC.
[Pt] Tipo de publicación:JOURNAL ARTICLE
[Em] Mes de ingreso:1802
[Cu] Fecha actualización por clase:180311
[Lr] Fecha última revisión:180311
[St] Status:In-Data-Review
[do] DOI:10.1097/PAS.0000000000000952



página 1 de 23307 va a la página                         
   


Refinar la búsqueda
  Base de datos : MEDLINE Formulario avanzado   

    Buscar en el campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPS/OMS - Centro Latinoamericano y del Caribe de Información en Ciencias de la Salud